CD30 expression in monomorphic posttransplant lymphoproliferative disorder, diffuse large b-cell lymphoma correlates with greater regulatory t-cell infiltration

Christopher Hartley, James Vaughan, Jason Jarzembowski, Steven H. Kroft, Paul Hosking, Alexandra M. Harrington, Horatiu Olteanu

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Objectives: CD30 is a protein thought to promote cell proliferation/survival and downregulate the immune response. Twenty percent to 40% of de novo diffuse large B-cell lymphomas (DLBCLs) express CD30, and some patients have been treated with the anti-CD30 agent brentuximab. In the solid organ transplant setting, allograft regulatory T cells (Tregs) have been shown to be modulated via CD30 signaling. Methods: Posttransplant lymphoproliferative disorders (PTLDs) constitute a heterogeneous group of lymphomas, and since CD30 expression has been rarely formally assessed in PTLDs, we analyzed a cohort of PTLDs. Results: We found that 26 (79%) of 33 PTLDs were CD30+. Of these, 17 (77%) of 22 DLBCL monomorphic PTLDs were CD30+ compared with 56 (38%) of 148 de novo DLBCLs (P = .009). The median FoxP3+ Treg count was higher in CD30+ than in CD30- PTLDs, 3.0 vs 0 (P = .012). Conclusions: These findings suggest a pathophysiologic link between CD30 activity and Tregs and may indicate differential expression of CD30 in B-cell lymphomas arising in the setting of immune dysregulation.

Original languageEnglish (US)
Pages (from-to)485-493
Number of pages9
JournalAmerican Journal of Clinical Pathology
Volume148
Issue number6
DOIs
StatePublished - Dec 1 2017
Externally publishedYes

Fingerprint

Lymphoproliferative Disorders
Lymphoma, Large B-Cell, Diffuse
B-Cell Lymphoma
Regulatory T-Lymphocytes
Allografts
Lymphoma
Cell Survival
Down-Regulation
Cell Proliferation
Transplants
Proteins

All Science Journal Classification (ASJC) codes

  • Pathology and Forensic Medicine

Cite this

CD30 expression in monomorphic posttransplant lymphoproliferative disorder, diffuse large b-cell lymphoma correlates with greater regulatory t-cell infiltration. / Hartley, Christopher; Vaughan, James; Jarzembowski, Jason; Kroft, Steven H.; Hosking, Paul; Harrington, Alexandra M.; Olteanu, Horatiu.

In: American Journal of Clinical Pathology, Vol. 148, No. 6, 01.12.2017, p. 485-493.

Research output: Contribution to journalArticle

Hartley, Christopher ; Vaughan, James ; Jarzembowski, Jason ; Kroft, Steven H. ; Hosking, Paul ; Harrington, Alexandra M. ; Olteanu, Horatiu. / CD30 expression in monomorphic posttransplant lymphoproliferative disorder, diffuse large b-cell lymphoma correlates with greater regulatory t-cell infiltration. In: American Journal of Clinical Pathology. 2017 ; Vol. 148, No. 6. pp. 485-493.
@article{1308a6a283164529866caa1e5e79610e,
title = "CD30 expression in monomorphic posttransplant lymphoproliferative disorder, diffuse large b-cell lymphoma correlates with greater regulatory t-cell infiltration",
abstract = "Objectives: CD30 is a protein thought to promote cell proliferation/survival and downregulate the immune response. Twenty percent to 40{\%} of de novo diffuse large B-cell lymphomas (DLBCLs) express CD30, and some patients have been treated with the anti-CD30 agent brentuximab. In the solid organ transplant setting, allograft regulatory T cells (Tregs) have been shown to be modulated via CD30 signaling. Methods: Posttransplant lymphoproliferative disorders (PTLDs) constitute a heterogeneous group of lymphomas, and since CD30 expression has been rarely formally assessed in PTLDs, we analyzed a cohort of PTLDs. Results: We found that 26 (79{\%}) of 33 PTLDs were CD30+. Of these, 17 (77{\%}) of 22 DLBCL monomorphic PTLDs were CD30+ compared with 56 (38{\%}) of 148 de novo DLBCLs (P = .009). The median FoxP3+ Treg count was higher in CD30+ than in CD30- PTLDs, 3.0 vs 0 (P = .012). Conclusions: These findings suggest a pathophysiologic link between CD30 activity and Tregs and may indicate differential expression of CD30 in B-cell lymphomas arising in the setting of immune dysregulation.",
author = "Christopher Hartley and James Vaughan and Jason Jarzembowski and Kroft, {Steven H.} and Paul Hosking and Harrington, {Alexandra M.} and Horatiu Olteanu",
year = "2017",
month = "12",
day = "1",
doi = "10.1093/AJCP/AQX097",
language = "English (US)",
volume = "148",
pages = "485--493",
journal = "American Journal of Clinical Pathology",
issn = "0002-9173",
publisher = "American Society of Clinical Pathologists",
number = "6",

}

TY - JOUR

T1 - CD30 expression in monomorphic posttransplant lymphoproliferative disorder, diffuse large b-cell lymphoma correlates with greater regulatory t-cell infiltration

AU - Hartley, Christopher

AU - Vaughan, James

AU - Jarzembowski, Jason

AU - Kroft, Steven H.

AU - Hosking, Paul

AU - Harrington, Alexandra M.

AU - Olteanu, Horatiu

PY - 2017/12/1

Y1 - 2017/12/1

N2 - Objectives: CD30 is a protein thought to promote cell proliferation/survival and downregulate the immune response. Twenty percent to 40% of de novo diffuse large B-cell lymphomas (DLBCLs) express CD30, and some patients have been treated with the anti-CD30 agent brentuximab. In the solid organ transplant setting, allograft regulatory T cells (Tregs) have been shown to be modulated via CD30 signaling. Methods: Posttransplant lymphoproliferative disorders (PTLDs) constitute a heterogeneous group of lymphomas, and since CD30 expression has been rarely formally assessed in PTLDs, we analyzed a cohort of PTLDs. Results: We found that 26 (79%) of 33 PTLDs were CD30+. Of these, 17 (77%) of 22 DLBCL monomorphic PTLDs were CD30+ compared with 56 (38%) of 148 de novo DLBCLs (P = .009). The median FoxP3+ Treg count was higher in CD30+ than in CD30- PTLDs, 3.0 vs 0 (P = .012). Conclusions: These findings suggest a pathophysiologic link between CD30 activity and Tregs and may indicate differential expression of CD30 in B-cell lymphomas arising in the setting of immune dysregulation.

AB - Objectives: CD30 is a protein thought to promote cell proliferation/survival and downregulate the immune response. Twenty percent to 40% of de novo diffuse large B-cell lymphomas (DLBCLs) express CD30, and some patients have been treated with the anti-CD30 agent brentuximab. In the solid organ transplant setting, allograft regulatory T cells (Tregs) have been shown to be modulated via CD30 signaling. Methods: Posttransplant lymphoproliferative disorders (PTLDs) constitute a heterogeneous group of lymphomas, and since CD30 expression has been rarely formally assessed in PTLDs, we analyzed a cohort of PTLDs. Results: We found that 26 (79%) of 33 PTLDs were CD30+. Of these, 17 (77%) of 22 DLBCL monomorphic PTLDs were CD30+ compared with 56 (38%) of 148 de novo DLBCLs (P = .009). The median FoxP3+ Treg count was higher in CD30+ than in CD30- PTLDs, 3.0 vs 0 (P = .012). Conclusions: These findings suggest a pathophysiologic link between CD30 activity and Tregs and may indicate differential expression of CD30 in B-cell lymphomas arising in the setting of immune dysregulation.

UR - http://www.scopus.com/inward/record.url?scp=85038129680&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85038129680&partnerID=8YFLogxK

U2 - 10.1093/AJCP/AQX097

DO - 10.1093/AJCP/AQX097

M3 - Article

VL - 148

SP - 485

EP - 493

JO - American Journal of Clinical Pathology

JF - American Journal of Clinical Pathology

SN - 0002-9173

IS - 6

ER -